Brief: Cipla Updates On USFDA Inspection At Bommasandra Facility
05/08/2025 04:36
Aug 5 (Reuters) - Cipla Ltd CIPL.NS: CIPLA LTD - UPDATE ON USFDA INSPECTION AT CIPLA'S BOMMASANDRA FACILITY CIPLA LTD - USFDA CLASSIFIES CIPLA INSPECTION AS VOLUNTARY ACTION INDICATED Source text: ID:nNSE7t3YP9 Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated